Skip to main content
Year archive

Swedish Orphan Biovitrum — 2021 filings

All 31 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2021, sourced directly from the official regulator.

31 Filings
2021 Period
2021 filings (31)
Filing Released Lang
Kineret® (anakinra) erhåller positivt utlåtande från CHMP för behandling av patienter med covid-19-orsakad lunginflammation
Regulatory Filings
2021-12-16 Swedish
Kineret® (anakinra) receives positive opinion from the CHMP for treatment of patients with COVID-19 pneumonia
Regulatory Filings
2021-12-16 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q3 2021
2021-10-22 Swedish
Earnings Release 2021
Earnings Release 9M 2021
2021-10-22 English
Aspaveli® (pegcetacoplan) får positivt utlåtande från CHMP för behandling av PNH
Regulatory Filings
2021-10-15 Swedish
Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
Regulatory Filings
2021-10-15 English
Sobi announces preliminary headline numbers for the third quarter and the period January to September 2021 in view of the ongoing public offer for Sobi
Earnings Release 9M 2021
2021-10-11 English
Sobi offentliggör preliminära siffror för tredje kvartalet och för perioden januari till september 2021 med anledning av det pågående offentliga erbjudandet avseende Sobi
Earnings Release 9M 2021
2021-10-11 Swedish
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2021-09-30 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2021-09-30 English
Statement by the Board of Directors of Swedish Orphan Biovitrum AB in relation to the public cash offer by Advent and GIC
M&A Activity
2021-09-02 English
Uttalande från styrelsen för Swedish Orphan Biovitrum AB med anledning av Advents och GIC:s offentliga kontanterbjudande
M&A Activity
2021-09-02 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-07-21 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-07-21 English
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Share Issue/Capital Change
2021-07-20 Swedish
The Board of directors exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme
Transaction in Own Shares
2021-07-20 English
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
Earnings Release FY 2021
2021-05-25 English
Positiva topline-resultat från fas 3-studien PRINCE med pegcetacoplan hos behandlingsnaiva patienter med PNH
Regulatory Filings
2021-05-25 Swedish
Bulletin from Swedish Orphan Biovitrum’s (“Sobi”) Annual General Meeting (AGM)
AGM Information
2021-05-04 English
Kommuniké från Swedish Orphan Biovitrums (”Sobi”) årsstämma
AGM Information
2021-05-04 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-04 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-04 English
Sobi and Hellenic Institute for the Study of Sepsis: anakinra improved overall clinical outcomes by 64% in hospitalised patients with COVID-19 pneumonia
Regulatory Filings
2021-05-03 English
Sobi: anakinra förbättrade kliniskt utfall med 64% hos patienter inlagda med covid-19-relaterad lunginflammation
Regulatory Filings
2021-05-03 Swedish
Annual Report 2020
Annual Report FY 2020
2021-04-06 Swedish
Annual Report 2020
Annual Report FY 2020
2021-04-06 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2021-03-29 Swedish
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2021-03-29 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q4 2020
2021-02-18 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q4 2020
2021-02-18 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-01 English